Tue, Sep 23, 2014, 12:37 PM EDT - U.S. Markets close in 3 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

QuadraMed Corporation (QMDCE) Message Board

  • SftwDude SftwDude Oct 28, 1999 4:49 PM Flag

    Scary....

    Shared Medical Systems released their 3rd
    QTR:

    -- On Wednesday, after the close, Shared Medical
    reported 3Q99 EPS of $0.80, which met the consensus
    estimate and was one cent better than Warburg's
    projection. But it also warned of a shortfall
    ahead.

    Meet estimates every thing should be okay,
    right?

    Wronge, they got hammered today

    DOWN 6 3/16
    -14.69%

    You need to read the financial report for 3rd QTR. It
    reads a lot like QMDC type stuff.

    It scares me
    to think that they met estimates, same health care
    related issues that QMDC has, and got HAMMERED.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • QMDC beat what the street was expecting for 3Q by
      maybe 20% and has ALREADY guided the street down to .03
      or .04 for 4Q, which they will probably surpass a la
      Microsoft's long-held strategy of guiding analysts to the low
      side. This was Shared Medical's first formal warning,
      so perhaps QMDC is being clever here, and with over
      2 million shares shorted --- or 10% of the float
      --- maybe the shorts will be screwed tomorrow trying
      to cover under $6.

    • RICHMOND, Calif., Oct 28, 1999 (BW HealthWire) --
      QuadraMed
      Corporation (NASDAQ:QMDC) announced today
      results for its third quarter
      ended September 30,
      1999. For the third quarter, the Company reported

      earnings of $0.15 per diluted share, assuming a 40% tax
      rate.

      For the three-month period ended
      September 30, 1999, total revenues
      increased to
      $62,057,000. For the quarter, the Company reported an 11%

      sequential increase in license revenue. Net income during
      the quarter,
      which includes a charge of
      $1,722,000 for the write-off of acquired
      research and
      development in process, was $4,527,000. Diluted earnings

      per share for the quarter were $0.18. Assuming a 40%
      tax rate and
      excluding the charge above, the
      Company reported net income of $3,895,
      000, or $0.15
      per diluted share.

      For the comparable
      three-month period last year, total revenues were

      $56,947,000. Including non-operating charges totaling
      $10,844,000, the
      Company reported a net loss of
      $3,366,000, or $0.14 per diluted share.
      Excluding the
      charges above, the Company reported net income of $5,399,

      000, or $0.21 per diluted share using fully diluted
      shares of 25,286,
      000. Financial results are
      restated to reflect historical pooling of
      interest
      transactions.

      For the nine-month period ended September
      30, 1999, total revenues
      increased to
      $179,733,000. Including non-operating charges totaling $37,

      964,000, the Company reported a net loss of $14,620,000 or
      $0.59 per
      share. Excluding the above charges, the
      Company reported net income of
      $14,834,000 or $0.58
      per share, assuming a 40% tax rate and using fully

      diluted shares of 25,764,000.

      For the comparable
      nine-month period during the previous year, total

      revenues were $149,850,000. Including non-operating
      charges totaling
      $28,950,000, the Company reported a
      net loss of $27,752,000, or $1.23
      per diluted
      share. Assuming a 40% tax rate and excluding the charges

      above, the Company reported net income of $2,815,000, or
      $0.12 per
      share using fully diluted shares of
      24,364,000.

      Jim Durham, Chairman and Chief Executive
      Officer said. "We are pleased
      with our sustained
      contract signing activity and the prospects for
      2000.
      During the quarter, we posted a sequential increase in
      license
      revenue for the first time in 1999. Our cross
      selling success
      continues, having sold once again,
      roughly 70 percent of our products
      and services into
      our existing customer base. We believe we are still

      on track to generate cash from operations during the
      first quarter of
      2000."

      QuadraMed
      Corporation uses technology to transform disparate healthcare

      data into valuable, enterprise-wide information.
      Providing and
      distributing meaningful information
      through its software, services and
      Internet
      solutions, Quadramed has enabled its 4,000 customers in the

      U.S. and Canada to generate operational efficiencies,
      improve cash flow
      and measure the cost and quality of
      care. QuadraMed has implemented its
      product and
      service solutions in approximately 60% of the nation�s

      hospitals.

      The Company has a significant talent pool
      that--through its active
      participation in professional and
      trade organizations--has helped to
      shape the
      healthcare information technology industry. The Company has

      substantial expertise in the core components stipulated
      within the
      HIPAA legislation spanning a wide range
      of products, services and
      education. These core
      components include security management across
      diverse
      applications and organizations, confidentiality in electronic

      data transactions and development of health
      information policy,
      procedure management and readiness
      consulting services. For more
      information about
      QuadraMed, its products and services, visit

      http://www.quadramed.com.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.